Table 2.
Statistical associations between CCNB2 mRNA expression and clinic-pathological parameters in the METABRIC (n=1980) and TCGA (n=854) breast carcinoma datasets
| Parameters | CCNB2 mRNA (METABRIC) | CCNB2 mRNA (TCGA) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Number (%) | Mean Rank | P-value | Number (%) | Mean Rank | P-value | |
| Patient Age (year) | ||||||
| ≤50 | 424 (21.4) | 8.25 | <0.0001 | 231 (27) | 466.3 | 0.005 |
| >50 | 1556 (78.6) | 7.95 | 623 (73) | 413.1 | ||
| Tumour Size | ||||||
| ≤2 cm | 622 (31.7) | 7.58 | <0.0001 | 239 (28) | 362.5 | <0.0001 |
| >2 cm | 1338 (68.3) | 8.09 | 615 (72) | 452.8 | ||
| Tumour Grade | ||||||
| 1 | 170 (9) | 7.16 | <0.0001 | 89 (11) | 198.5 | <0.0001 |
| 2 | 770 (40.6) | 7.66 | 375 (46) | 308.3 | ||
| 3 | 952 (50.4) | 8.50 | 352 (43) | 568.4 | ||
| Nodal Status | ||||||
| Negative | 1035 (52.5) | 7.90 | <0.0001 | 426 (51) | 418.5 | 0.439 |
| Positive | 938 (47.5) | 8.14 | 423 (49) | 431.5 | ||
| Lympho-vascular Invasion | ||||||
| Negative | 930 (59.4) | 7.93 | <0.0001 | 559 (65) | 392.5 | <0.0001 |
| Positive | 635 (40.6) | 8.10 | 295 (35) | 493.8 | ||
| Oestrogen Receptor | ||||||
| Negative | 474 (23.9) | 8.77 | <0.0001 | 185 (22) | 625.7 | <0.0001 |
| Positive | 1506 (76.1) | 7.78 | 639 (78) | 350.8 | ||
| Progesterone Receptor | ||||||
| Negative | 940 (47.4) | 8.53 | <0.0001 | 272 (33) | 552.1 | <0.0001 |
| Positive | 1040 (52.6) | 7.71 | 546 (67) | 338.4 | ||
| HER2 Status | ||||||
| Negative | 1733 (87.5) | 7.94 | <0.0001 | 567 (81) | 339.1 | 0.002 |
| Positive | 247 (12.5) | 8.52 | 133 (19) | 399.1 | ||
| Immunohistochemistry subtypes | ||||||
| ER+/HER2- Low Proliferation | 368 (36.9) | 8.74 | <0.0001 | Not available | ||
| ER+/HER2- High Proliferation | 368 (36.9) | 8.37 | ||||
| Triple Negative | 151 (15.1) | 7.19 | ||||
| HER2+ | 110 (11.1) | 8.52 | ||||
Significant P values are in bold.